Shares of other companies:
April 26, 2024 Top 10 High Dividend Yield Stocks
April 24, 2024 Google’s Third Cookie Phaseout Delay Amid Regulatory Hurdles
Tesla Q1: Model 2 Could Be Their Model T
April 25, 2024
Tesla Is An AI Company That The Market Won’t Reward For Now
April 24, 2024
Amazon: The Margin Train Is Gaining Speed
April 24, 2024
April 23, 2024 Maximizing Profits: When is the Right Time to Sell Your Business?
Selling a business can be a momentous decision filled with many considerations and uncertainties. As an entrepreneur, this also symbolizes your years of…
April 12, 2024 Improve Your Financial Status: A How-To Guide
Navigating through the complexities of personal finance can often feel like walking through a maze blindfolded. This guide is crafted especially for you,…
April 12, 2024 How ZIM Integrated Container Tracking is Revolutionizing Global Trade
Have you ever wondered how your online shopping packages get to you? A big part of the answer is ZIM Integrated Container Tracking.…
March 15, 2024 6 Best Growth Stocks To Buy Now According to Metatrader 5
One of the reasons investors prefer growth stocks is that they are expected to perform better than other companies in terms of sales…
ALPN Stock News and Mentions of Alpine Immune Sciences, Inc. Stocktwits
Updated: April 26, 2024 (09:55)
Sector: Healthcare
Welcome to PandaPulse, innovative analytical stock market observer, where the latest news and stocktwits meets in-depth investor relations insights. Dive into our real-time sentiment analysis to gauge the mood of the markets and arm yourself with key information that resonates with both savvy investors and casual traders.
We meticulously analyze the sentiment trend in each article for the last 60 days where Alpine Immune Sciences Company is mentioned. We assess its relevance and importance to carry out an overall sentiment valuation of Alpine Immune Sciences, Inc. (ALPN).
You can view the trend designation for each individual article below. We use this data to compile indicators into one comprehensive sentiment value, which represents the current information agenda about the Alpine Immune Sciences stocks.
Please wait, while the data is preparing...
General evaluation of the current information agenda's sentiments
Agenda Trend
Analyzed articles
News and Mentions of Alpine Immune Sciences, Inc. (ALPN)
April 26, 2024 (09:00) / "Financial Times" (by Oliver Barnes)
Its blockbuster cystic fibrosis treatment costs $300,000 a year. Now Vertex wants to solve the opioid crisis
With revenues having more than doubled since 2019, to $10bn, US pharma group targets painkillers ...
In Article Trend: Neutral
April 25, 2024 (12:33) / "Zacks Commentary" (by Zacks Equity Research)
Zacks Industry Outlook Highlights Eli Lilly, Novo Nordisk, Merck and AbbVie
Eli Lilly, Novo Nordisk, Merck and AbbVie are part of the Zacks Industry Outlook article.
In Article Trend: Somewhat-Bullish
April 25, 2024 (07:00) / "Investors Business Daily" (by Investor's Business Daily)
Avalo Therapeutics Clears Key Benchmark, Hitting 90-Plus RS Rating
On Thursday, Avalo Therapeutics ( AVTX ) received a positive adjustment to its Relative Strength ( RS ) Rating, from 89 to 93. X IBD's unique rating identifies market leadership with a 1 ( worst ) to 99 ( best ) score.
In Article Trend: Bullish
April 24, 2024 (07:00) / "Investors Business Daily" (by INVESTOR'S BUSINESS DAILY)
Day One Biopharm Shows Market Leadership With Jump To 92 RS Rating
Day One Biopharm ( DAWN ) had its Relative Strength ( RS ) Rating upgraded from 88 to 92 Wednesday. X IBD's proprietary RS Rating identifies market leadership by using a 1 ( worst ) to 99 ( best ) score that indicates how a stock's price performance over the last 52 weeks matches up against ...
In Article Trend: Bullish
April 24, 2024 (07:00) / "Investors Business Daily" (by INVESTOR'S BUSINESS DAILY)
IBD Rating Upgrades: Ultragenyx Pharm Flashes Improved Price Strength
The Relative Strength ( RS ) Rating for Ultragenyx Pharm ( RARE ) moved into a higher percentile Wednesday, as it got a lift from 64 to 73. X This proprietary rating identifies technical performance by showing how a stock's price action over the last 52 weeks compares to that of the other ...
In Article Trend: Somewhat-Bullish
April 24, 2024 (07:00) / "Investors Business Daily" (by INVESTOR'S BUSINESS DAILY)
Roivant Sciences Gets RS Rating Upgrade
Roivant Sciences ( ROIV ) had its Relative Strength ( RS ) Rating upgraded from 70 to 73 Wednesday - a welcome improvement, but still below the 80 or better score you look for. X This exclusive rating from Investor's Business Daily tracks price performance with a 1 ( worst ) to 99 ( best ) ...
In Article Trend: Bullish
April 23, 2024 (10:05) / "Motley Fool" (by Adria Cimino)
Vertex Pharmaceuticals Just Made 2 Big Moves. Is the Stock a Buy?
Vertex is broadening its portfolio.
In Article Trend: Somewhat-Bullish
April 23, 2024 (07:00) / "Investors Business Daily" (by INVESTOR'S BUSINESS DAILY)
Stocks To Watch: Rocket Pharmaceuticals Sees Relative Strength Rating Jump To 81
On Tuesday, Rocket Pharmaceuticals ( RCKT ) received an upgrade to its Relative Strength ( RS ) Rating, from 73 to 81. X This proprietary rating tracks technical performance by showing how a stock's price action over the last 52 weeks measures up against that of the other stocks in our database.
In Article Trend: Somewhat-Bullish
April 23, 2024 (07:00) / "Investors Business Daily" (by Investor's Business Daily)
Exelixis Getting Closer To Key Technical Benchmark
Exelixis ( EXEL ) had its Relative Strength ( RS ) Rating upgraded from 69 to 75 Tuesday - a welcome improvement, but still short of the 80 or better score you look for.
In Article Trend: Bullish
April 22, 2024 (21:33) / "Benzinga" (by Globe Newswire)
TAKE ACTION: The M&A Class Action Firm Launches Legal Inquiry for the Merger - ALPN, LABP, SWAV, FUSN
NEW YORK, April 22, 2024 ( GLOBE NEWSWIRE ) -- Monteverde & Associates PC ( the "M&A Class Action Firm" ) , has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report.
In Article Trend: Somewhat-Bullish
April 22, 2024 (15:12) / "Benzinga" (by Globe Newswire)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates INRD, AIRC, ELYM, ALPN - Apartment Income REIT ( NYSE:AIRC ) , Alpine Immune Sciences ( NASDAQ:ALPN )
NEW YORK, April 22, 2024 ( GLOBE NEWSWIRE ) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Inrad Optics, Inc.
In Article Trend: Somewhat-Bullish
April 22, 2024 (13:48) / "Benzinga" (by Globe Newswire)
Kuehn Law Encourages INRD, AIRC, ELYM, and ALPN Investors to Contact Law Firm - Apartment Income REIT ( NYSE:AIRC ) , Alpine Immune Sciences ( NASDAQ:ALPN )
NEW YORK, April 22, 2024 ( GLOBE NEWSWIRE ) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law may seek additional disclosures or other relief on behalf of the shareholders of these companies.
In Article Trend: Somewhat-Bullish
April 22, 2024 (13:03) / "Motley Fool" (by Motley Fool Staff)
Making Sense of Amazon CEO Andy Jassy's Latest Letter
And that's just part of the interesting news for investors to dig into.
In Article Trend: Neutral
April 22, 2024 (09:52) / "Motley Fool" (by Keith Speights)
Looking for Once-in-a-Generation Investment Opportunities? Here Are 3 Magnificent Stocks to Buy Right Now
These stocks could be near major inflection points.
In Article Trend: Somewhat-Bullish
April 22, 2024 (07:00) / "Investors Business Daily" (by Investor's Business Daily)
Syndax Pharmaceuticals Earns Relative Strength Rating Upgrade; Hits Key Threshold
Syndax Pharmaceuticals Earns Relative Strength Rating Upgrade. Hits Key Threshold Investor's Business Daily ...
In Article Trend: Somewhat-Bullish
April 20, 2024 (10:48) / "Motley Fool" (by David Jagielski)
3 Relatively Safe Growth Stocks You Can Buy and Hold
Low risk and high-reward potential? These stocks could offer both.
In Article Trend: Somewhat-Bullish
April 19, 2024 (08:30) / "Motley Fool" (by David Jagielski)
Is Vertex Pharmaceuticals Stock a Millionaire Maker?
Does this pharma stock have the potential to turn a $25,000 investment into seven figures or more?
In Article Trend: Somewhat-Bullish
April 19, 2024 (07:00) / "Investors Business Daily" (by INVESTOR'S BUSINESS DAILY)
Bicycle Therapeutics ADR Clears Technical Benchmark, Hitting 90-Plus RS Rating
Bicycle Therapeutics ADR ( BCYC ) had its Relative Strength ( RS ) Rating upgraded from 79 to 90 Friday. X This proprietary rating measures technical performance by using a 1 ( worst ) to 99 ( best ) score that identifies how a stock's price action over the trailing 52 weeks matches up ...
In Article Trend: Somewhat-Bullish
April 19, 2024 (07:00) / "Investors Business Daily" (by INVESTOR'S BUSINESS DAILY)
Madrigal Pharmaceuticals Getting Closer To Key Technical Measure
Madrigal Pharmaceuticals ( MDGL ) saw a positive improvement to its Relative Strength ( RS ) Rating on Friday, rising from 69 to 73.
In Article Trend: Bullish
April 18, 2024 (12:30) / "Motley Fool" (by Prosper Junior Bakiny)
Does This Acquisition Make Vertex Pharmaceuticals Stock a Buy?
The biotech just added another potential growth driver to its pipeline.
In Article Trend: Somewhat-Bullish
April 18, 2024 (07:00) / "Investors Business Daily" (by Investor's Business Daily)
Celldex Therapeutics Hits 80-Plus Relative Strength Rating Benchmark
On Thursday, Celldex Therapeutics ( CLDX ) got an upgrade to its Relative Strength ( RS ) Rating, from 77 to 83. X IBD's unique rating identifies market leadership with a 1 ( worst ) to 99 ( best ) score. The rating shows how a stock's price movement over the trailing 52 weeks compares to all ...
In Article Trend: Somewhat-Bullish
April 17, 2024 (07:00) / "Investors Business Daily" (by Investor's Business Daily)
Stocks To Watch: Day One Biopharm Sees RS Rating Rise To 84
One important metric to look for in a stock is an 80 or higher Relative Strength Rating. Day One Biopharm ( DAWN ) now clears that threshold, with a jump from 74 to 84 Wednesday.
In Article Trend: Bullish
April 17, 2024 (07:00) / "Investors Business Daily" (by INVESTOR'S BUSINESS DAILY)
Exelixis Getting Closer To Key Technical Benchmark
Exelixis ( EXEL ) had its Relative Strength ( RS ) Rating upgraded from 68 to 71 Wednesday - a welcome improvement, but still below the 80 or better score you prefer to see.
In Article Trend: Bullish
April 17, 2024 (07:00) / "Investors Business Daily" (by INVESTOR'S BUSINESS DAILY)
Stocks To Watch: Avalo Therapeutics Sees Relative Strength Rating Jump To 95
Avalo Therapeutics ( AVTX ) saw a welcome improvement to its Relative Strength ( RS ) Rating on Wednesday, rising from 83 to 95. X This proprietary rating identifies technical performance by showing how a stock's price action over the last 52 weeks compares to that of the other stocks in our ...
In Article Trend: Bullish
April 17, 2024 (07:00) / "Investors Business Daily" (by Investor's Business Daily)
Stocks With Rising Relative Price Strength: Revolution Medicines
Revolution Medicines ( RVMD ) had its Relative Strength ( RS ) Rating upgraded from 89 to 92 Wednesday. X IBD's unique rating measures market leadership with a 1 ( worst ) to 99 ( best ) score. The rating shows how a stock's price movement over the trailing 52 weeks compares to all the other ...
In Article Trend: Somewhat-Bullish
April 16, 2024 (12:11) / "Benzinga" (by Globe Newswire)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MGRC, ALPN, NXPL - Alpine Immune Sciences ( NASDAQ:ALPN ) , McGrath RentCorp ( NASDAQ:MGRC )
NEW YORK, April 16, 2024 ( GLOBE NEWSWIRE ) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
In Article Trend: Somewhat-Bullish
April 16, 2024 (07:00) / "Investors Business Daily" (by INVESTOR'S BUSINESS DAILY)
Stocks With Rising Relative Price Strength: Avadel Pharmaceuticals
On Tuesday, Avadel Pharmaceuticals ( AVDL ) got a positive adjustment to its Relative Strength ( RS ) Rating, from 88 to 91. X IBD's unique RS Rating measures market leadership by using a 1 ( worst ) to 99 ( best ) score that indicates how a stock's price action over the last 52 weeks matches ...
In Article Trend: Somewhat-Bullish
April 15, 2024 (13:15) / "Motley Fool" (by Alex Carchidi)
Here's ( at Least ) 1 new Reason to Buy Vertex Pharmaceuticals Stock
Vertex just laid claim to an asset that might be very valuable.
In Article Trend: Somewhat-Bullish
April 13, 2024 (09:29) / "Motley Fool" (by Cory Renauer)
Could This Stock Be the Next Biotech Buyout?
Vertex Pharmaceuticals' $4.9 billion purchase of Alpine Immune Sciences probably won't be the last acquisition of a company focused on kidney disease.
In Article Trend: Neutral
April 12, 2024 (16:38) / "Investors Business Daily" (by Investor's Business Daily)
Market Signals Mixed; Nvidia, Inflation, Iran In Focus: Weekly Review
Market Signals Mixed. Nvidia, Inflation, Iran In Focus: Weekly Review Investor's Business Daily ...
In Article Trend: Neutral
April 12, 2024 (16:36) / "Zacks Commentary" (by Zacks Equity Research)
Alpine ( ALPN ) Surges 37% on $4.9B Buyout Offer From Vertex
Vertex (VRTX) is set to acquire Alpine Immune Sciences (ALPN) for $65 per share in cash. The transaction is likely to close by second-quarter 2024.
In Article Trend: Somewhat-Bullish
April 12, 2024 (07:00) / "Investors Business Daily" (by INVESTOR'S BUSINESS DAILY)
Stocks Flashing Renewed Technical Strength: Syndax Pharmaceuticals
Syndax Pharmaceuticals ( SNDX ) had its Relative Strength ( RS ) Rating upgraded from 79 to 83 Friday. X IBD's unique rating tracks price movement with a 1 ( worst ) to 99 ( best ) score. The grade shows how a stock's price performance over the trailing 52 weeks compares to all the other ...
In Article Trend: Somewhat-Bullish
April 12, 2024 (07:00) / "Investors Business Daily" (by INVESTOR'S BUSINESS DAILY)
Ligand Pharmaceuticals Earns Relative Strength Rating Upgrade; Hits Key Benchmark
Ligand Pharmaceuticals Earns Relative Strength Rating Upgrade. Hits Key Benchmark Investor's Business Daily ...
In Article Trend: Bullish
April 12, 2024 (07:00) / "Investors Business Daily" (by INVESTOR'S BUSINESS DAILY)
IBD Rating Upgrades: Cassava Sciences Flashes Improved Relative Price Strength
Cassava Sciences ( SAVA ) had its Relative Strength ( RS ) Rating upgraded from 69 to 76 Friday - a welcome improvement, but still shy of the 80 or higher score you look for. X IBD's proprietary rating tracks market leadership with a 1 ( worst ) to 99 ( best ) score.
In Article Trend: Somewhat-Bullish
April 11, 2024 (19:12) / "Business Insider" (by Vandana Singh)
Vertex's Alpine Acquisition: Unpacking Analyst Predictions on Povetacicept's Potential Impact
On Wednesday, Vertex Pharmaceuticals Incorporated ( NASDAQ:VRTX ) agreed to acquire Alpine Immune Sciences Inc ( NASDAQ:ALPN ) for $65 per share or approximately $4.9 billion in cash.
In Article Trend: Somewhat-Bullish
April 11, 2024 (18:47) / "Benzinga" (by Vandana Singh)
Vertex's Alpine Acquisition: Unpacking Analyst Predictions on Povetacicept's Potential Impact - Vertex Pharmaceuticals ( NASDAQ:VRTX )
On Wednesday, Vertex Pharmaceuticals Incorporated VRTX agreed to acquire Alpine Immune Sciences Inc ALPN for $65 per share or approximately $4.9 billion in cash.
In Article Trend: Somewhat-Bullish
April 11, 2024 (14:01) / "Benzinga" (by Avi Kapoor)
Enliven Therapeutics, Alpine Immune Sciences, Janux Therapeutics And Other Big Stocks Moving Higher On Thursday - Janux Therapeutics ( NASDAQ:JANX ) , Alpine Immune Sciences ( NASDAQ:ALPN ) , Enliven Therapeutics ( NASDAQ:ELVN )
U.S. stocks were mixed, with the Dow Jones index falling over 50 points on Thursday. Shares of Enliven Therapeutics, Inc. ELVN rose sharply during Thursday's session. Enliven Therapeutics announced proof of concept data from Phase 1 clinical trial of ELVN-001 in chronic myeloid leukemia.
In Article Trend: Somewhat-Bullish
April 11, 2024 (13:17) / "Investors Business Daily" (by Investor's Business Daily)
Biotech Stocks Heat Up, Driven By A Spate Of Billion-Dollar Deals
Biotech Stocks Heat Up As Arvinas Scores Licensing Deal And Janux Reportedly Explores Options Investor's Business Daily ...
In Article Trend: Neutral
April 11, 2024 (13:01) / "Benzinga" (by Vandana Singh)
Vertex Pharmaceuticals Moves Beyond $10B Cystic Fibrosis Franchise, Pays Around $5B For Kidney Disease Player Alpine Immune Why Alpine Immune Sciences Stock Is Trading Higher Today? - Alpine Immune Sciences ( NASDAQ:ALPN ) , Vertex Pharmaceuticals ( NASDAQ:VRTX )
On Wednesday, Vertex Pharmaceuticals Incorporated VRTX agreed to acquire Alpine Immune Sciences Inc ALPN for $65 per share or approximately $4.9 billion in cash. Alpine's lead molecule, povetacicept ( ALPN-303 ) , is a highly potent and effective dual antagonist of BAFF ( B cell activating factor ...
In Article Trend: Somewhat-Bullish
April 11, 2024 (12:18) / "Investors Business Daily" (by ED CARSON)
Futures Fall Before Another Key Inflation Report
Stock Market Today: Dow Jones Futures Fall Ahead Of Inflation, Jobs Data. Nvidia, Microsoft Price Targets Raised Investor's Business Daily ...
In Article Trend: Neutral
April 11, 2024 (11:27) / "Benzinga" (by Shanthi Rexaline)
S&P 500, Nasdaq Set For Lower Open While Bitcoin Holds Above $70K: What's Moving Stock Futures? - Alpine Immune Sciences ( NASDAQ:ALPN )
The negative mood on Wall Street may persist as investors await the release of another inflation report, which will have significant implications for the near-term trend in consumer prices. Wholesale price inflation typically flows down the supply chain and manifests as higher retail prices in ...
In Article Trend: Neutral
April 11, 2024 (10:14) / "Benzinga" (by Avi Kapoor)
Why Rallybio Shares Are Trading Higher By Around 78%; Here Are 20 Stocks Moving Premarket - Rallybio ( NASDAQ:RLYB )
Shares of Rallybio Corporation RLYB rose sharply in today's pre-market trading after the company announced a collaboration with Johnson & Johnson to advance therapeutics for pregnant individuals at risk of FNAIT. Rallybio shares jumped rose 77.9% to $2.90 in pre-market trading.
In Article Trend: Neutral
April 11, 2024 (07:00) / "Investors Business Daily" (by INVESTOR'S BUSINESS DAILY)
Revolution Medicines Joins Rank Of Stocks With RS Ratings Over 90
Revolution Medicines ( RVMD ) had its Relative Strength ( RS ) Rating upgraded from 87 to 93 Thursday. X IBD's unique RS Rating identifies technical performance by showing how a stock's price action over the last 52 weeks measures up against that of the other stocks in our database.
In Article Trend: Somewhat-Bullish
April 11, 2024 (07:00) / "Investors Business Daily" (by INVESTOR'S BUSINESS DAILY)
Ultragenyx Pharm Earns Relative Strength Rating Upgrade; Hits Key Threshold
Ultragenyx Pharm Earns Relative Strength Rating Upgrade. Hits Key Threshold Investor's Business Daily ...
In Article Trend: Somewhat-Bullish
April 11, 2024 (07:00) / "Investors Business Daily" (by INVESTOR'S BUSINESS DAILY)
Exelixis Sees IBD RS Rating Improve To 71
On Thursday, Exelixis ( EXEL ) received an upgrade to its Relative Strength ( RS ) Rating, from 65 to 71. X IBD's unique rating tracks share price action with a 1 ( worst ) to 99 ( best ) score. The rating shows how a stock's price performance over the trailing 52 weeks compares to all the ...
In Article Trend: Bullish
April 11, 2024 (07:00) / "Investors Business Daily" (by INVESTOR'S BUSINESS DAILY)
IBD Rating Upgrades: MoonLake Immunotherap Shows Improved Price Strength
The Relative Strength ( RS ) Rating for MoonLake Immunotherap ( MLTX ) climbed into a new percentile Thursday, as it got a lift from 65 to 76.
In Article Trend: Somewhat-Bullish
April 11, 2024 (02:19) / "Benzinga" (by Benzinga Neuro)
MSTR, ADIL, ALPN, MRIN, TSLA: Top 5 Trending Stocks Today - Adial Pharmaceuticals ( NASDAQ:ADIL )
On Wednesday, key U.S. stock indexes closed lower, as the Dow Jones Industrial Average fell by 1.1% to 38,461.51, the S&P 500 dropped nearly 1% to 5,160.64, and the Nasdaq ended the day down by 0.8% at 16,170.36. These are the top stocks that gained the attention of retail traders and investors ...
In Article Trend: Somewhat-Bullish
April 10, 2024 (20:45) / "Investors Business Daily" (by ALLISON GATLIN)
Vertex Pharma Nabs Alpine Immune Sciences In $4.9 Billion Deal
Vertex Pharmaceuticals ( VRTX ) will pay $4.9 billion to acquire immunological-focused biotech Alpine Immune Sciences ( ALPN ) , the companies said late Wednesday. Alpine stock rocketed after-hours after soaring on rumors of the deal.
In Article Trend: Neutral
April 10, 2024 (19:07) / "Benzinga" (by Vandana Singh)
Why Is Alpine Immune Sciences Stock Trading Higher Today? - Alpine Immune Sciences ( NASDAQ:ALPN )
Alpine Immune Sciences Inc ALPN is reportedly considering strategic options, including a potential sale, following interest from potential buyers. The Seattle-based firm is working closely with advisors and evaluating various possibilities, and at least one major pharmaceutical player has ...
In Article Trend: Somewhat-Bullish
April 10, 2024 (07:00) / "Investors Business Daily" (by INVESTOR'S BUSINESS DAILY)
Agios Pharmaceuticals Scores Relative Strength Rating Upgrade; Hits Key Threshold
Agios Pharmaceuticals Scores Relative Strength Rating Upgrade. Hits Key Threshold Investor's Business Daily ...
In Article Trend: Somewhat-Bullish
April 10, 2024 (07:00) / "Investors Business Daily" (by INVESTOR'S BUSINESS DAILY)
Rocket Pharmaceuticals Gets Relative Strength Rating Upgrade
The Relative Strength ( RS ) Rating for Rocket Pharmaceuticals ( RCKT ) moved up into a new percentile Wednesday, as it got a lift from 69 to 77. X IBD's proprietary rating tracks market leadership with a 1 ( worst ) to 99 ( best ) score.
In Article Trend: Somewhat-Bullish
April 10, 2024 (07:00) / "Investors Business Daily" (by INVESTOR'S BUSINESS DAILY)
Stocks To Watch: Phathom Pharmaceuticals Sees RS Rating Jump To 86
On Wednesday, Phathom Pharmaceuticals ( PHAT ) hit an important technical milestone, seeing its Relative Strength ( RS ) Rating jump into the 80-plus percentile with an improvement to 86, up from 73 the day before.
In Article Trend: Somewhat-Bullish
April 9, 2024 (13:23) / "Zacks Commentary" (by Zacks Equity Research)
Alpine Immune Sciences ( ALPN ) Moves 10.4% Higher: Will This Strength Last?
Alpine Immune Sciences (ALPN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
In Article Trend: Somewhat-Bullish
April 9, 2024 (07:00) / "Investors Business Daily" (by Investor's Business Daily)
REGENXBIO Shows Rising Relative Strength; Still Shy Of Key Threshold
REGENXBIO Shows Rising Relative Strength. Still Shy Of Key Threshold Investor's Business Daily ...
In Article Trend: Somewhat-Bullish
April 9, 2024 (07:00) / "Investors Business Daily" (by Investor's Business Daily)
Structure Therap ADR Trying To Close In On Key Technical Benchmark
On Tuesday, Structure Therap ADR ( GPCR ) received a positive adjustment to its Relative Strength ( RS ) Rating, from 64 to 75. X IBD's unique rating measures share price movement with a 1 ( worst ) to 99 ( best ) score.
In Article Trend: Bullish
April 8, 2024 (07:00) / "Investors Business Daily" (by INVESTOR'S BUSINESS DAILY)
Revolution Medicines Earns Relative Strength Rating Upgrade; Hits Key Benchmark
Revolution Medicines Earns Relative Strength Rating Upgrade. Hits Key Benchmark Investor's Business Daily ...
In Article Trend: Somewhat-Bullish
April 8, 2024 (07:00) / "Investors Business Daily" (by Investor's Business Daily)
Stocks With Rising Relative Price Strength: Cabaletta Bio
When putting together your watch list, focus on stocks with an 80 or higher RS Rating. Cabaletta Bio ( CABA ) just cleared that benchmark with an upgrade from 79 to 83.
In Article Trend: Somewhat-Bullish
April 8, 2024 (07:00) / "Investors Business Daily" (by Investor's Business Daily)
Stocks With Rising Relative Strength: Phathom Pharmaceuticals
In a welcome move, Phathom Pharmaceuticals ( PHAT ) saw its Relative Strength Rating improve from 66 to 74 on Monday. X IBD's unique rating measures market leadership with a 1 ( worst ) to 99 ( best ) score.
In Article Trend: Bullish
April 8, 2024 (07:00) / "Investors Business Daily" (by Investor's Business Daily)
IBD Rating Upgrades: Ultragenyx Pharm Shows Improved Relative Price Strength
Ultragenyx Pharm ( RARE ) had its Relative Strength ( RS ) Rating upgraded from 66 to 77 Monday - a welcome improvement, but still shy of the 80 or higher score you prefer to see. X This exclusive rating from Investor's Business Daily tracks share price action with a 1 ( worst ) to 99 ( best ...
In Article Trend: Bullish
April 5, 2024 (07:00) / "Investors Business Daily" (by INVESTOR'S BUSINESS DAILY)
Ligand Pharmaceuticals Sees Relative Strength Rating Improve To 72
The Relative Strength ( RS ) Rating for Ligand Pharmaceuticals ( LGND ) moved up into a new percentile Friday, as it got a lift from 61 to 72. X This exclusive rating from Investor's Business Daily measures share price performance with a 1 ( worst ) to 99 ( best ) score.
In Article Trend: Bullish
April 4, 2024 (14:44) / "Benzinga" (by Avi Kapoor)
Lamb Weston Reports Weak Earnings, Joins Paragon 28, Resources Connection And Other Big Stocks Moving Lower On Thursday - Resources Connection ( NASDAQ:RGP ) , Lamb Weston Hldgs ( NYSE:LW )
U.S. stocks were higher, with the Dow Jones gaining over 150 points on Thursday. Shares of Lamb Weston Holdings, Inc. LW fell sharply during Thursday's session after the company reported weak third-quarter results and cut its FY24 outlook.
In Article Trend: Somewhat-Bearish
April 4, 2024 (07:00) / "Investors Business Daily" (by INVESTOR'S BUSINESS DAILY)
Stocks Showing Rising Market Leadership: Insmed Earns 82 RS Rating
Insmed ( INSM ) had its Relative Strength ( RS ) Rating upgraded from 72 to 82 Thursday. X This unique rating tracks technical performance by using a 1 ( worst ) to 99 ( best ) score that identifies how a stock's price performance over the trailing 52 weeks matches up against that of all ...
In Article Trend: Somewhat-Bullish
April 4, 2024 (07:00) / "Investors Business Daily" (by INVESTOR'S BUSINESS DAILY)
IBD Rating Upgrades: REGENXBIO Flashes Improved Technical Strength
The Relative Strength ( RS ) Rating for REGENXBIO ( RGNX ) climbed into a higher percentile Thursday, as it got a lift from 64 to 75. X IBD's proprietary RS Rating identifies market leadership by showing how a stock's price movement over the last 52 weeks measures up against that of the other ...
In Article Trend: Somewhat-Bullish
April 4, 2024 (07:00) / "Investors Business Daily" (by Investor's Business Daily)
Stocks Showing Improved Relative Strength: Roivant Sciences
Roivant Sciences ( ROIV ) saw a welcome improvement to its Relative Strength ( RS ) Rating on Thursday, rising from 70 to 79. X IBD's unique RS Rating measures market leadership by using a 1 ( worst ) to 99 ( best ) score that indicates how a stock's price action over the trailing 52 weeks ...
In Article Trend: Bullish
April 4, 2024 (07:00) / "Investors Business Daily" (by INVESTOR'S BUSINESS DAILY)
Supernus Pharmaceuticals Trying To Close In On Key Technical Benchmark
Supernus Pharmaceuticals ( SUPN ) had its Relative Strength ( RS ) Rating upgraded from 70 to 73 Thursday - a welcome improvement, but still shy of the 80 or better score you prefer to see.
In Article Trend: Bullish
April 4, 2024 (07:00) / "Investors Business Daily" (by Investor's Business Daily)
IBD Rating Upgrades: Azenta Flashes Improved Price Strength
In a welcome move, Azenta ( AZTA ) saw its Relative Strength Rating rise from 68 to 71 on Thursday. X This exclusive rating from Investor's Business Daily identifies price action with a 1 ( worst ) to 99 ( best ) score.
In Article Trend: Somewhat-Bullish
April 4, 2024 (07:00) / "Investors Business Daily" (by INVESTOR'S BUSINESS DAILY)
IBD Rating Upgrades: Arcturus Therapeutics Shows Improved Relative Price Strength
Arcturus Therapeutics ( ARCT ) had its Relative Strength ( RS ) Rating upgraded from 68 to 73 Thursday - a welcome improvement, but still shy of the 80 or higher score you prefer to see.
In Article Trend: Somewhat-Bullish
April 3, 2024 (07:00) / "Investors Business Daily" (by Investor's Business Daily)
Insmed Shows Improved Relative Price Performance; Still Shy Of Benchmark
Insmed Shows Improved Relative Price Performance. Still Shy Of Benchmark Investor's Business Daily ...
In Article Trend: Somewhat-Bullish
April 2, 2024 (07:00) / "Investors Business Daily" (by Investor's Business Daily)
Beam Therapeutics Hits 80-Plus Relative Strength Rating Benchmark
One important metric to look for in a stock is an 80 or higher Relative Strength Rating. Beam Therapeutics ( BEAM ) cleared that benchmark Tuesday, with a jump from 72 to 81 Tuesday. X IBD's proprietary rating measures share price performance with a 1 ( worst ) to 99 ( best ) score.
In Article Trend: Bullish
April 2, 2024 (07:00) / "Investors Business Daily" (by INVESTOR'S BUSINESS DAILY)
Stocks Generating Improved Relative Strength: REGENXBIO
REGENXBIO ( RGNX ) had its Relative Strength ( RS ) Rating upgraded from 70 to 78 Tuesday - a welcome improvement, but still short of the 80 or higher score you prefer to see.
In Article Trend: Somewhat-Bullish
April 1, 2024 (07:00) / "Investors Business Daily" (by Investor's Business Daily)
KalVista Pharmaceuticals Clears Key Benchmark, Hitting 80-Plus RS Rating
KalVista Pharmaceuticals ( KALV ) saw a welcome improvement to its Relative Strength ( RS ) Rating on Monday, rising from 69 to 82. X IBD's proprietary rating measures price action with a 1 ( worst ) to 99 ( best ) score.
In Article Trend: Bullish
April 1, 2024 (07:00) / "Investors Business Daily" (by INVESTOR'S BUSINESS DAILY)
Stocks To Watch: Syndax Pharmaceuticals Sees Relative Strength Rating Rise To 81
On Monday, Syndax Pharmaceuticals ( SNDX ) reached a noteworthy technical benchmark, with its Relative Strength ( RS ) Rating entering into the 80-plus percentile with an improvement to 81, a rise from 74 the day before.
In Article Trend: Somewhat-Bullish
April 1, 2024 (07:00) / "Investors Business Daily" (by INVESTOR'S BUSINESS DAILY)
Stocks To Watch: Revolution Medicines Sees RS Rating Jump To 81
One important metric to look for in a stock is an 80 or higher Relative Strength Rating. Revolution Medicines ( RVMD ) cleared that benchmark Monday, with a jump from 77 to 81 Monday. X IBD's unique rating identifies market leadership with a 1 ( worst ) to 99 ( best ) score.
In Article Trend: Bullish
April 1, 2024 (07:00) / "Investors Business Daily" (by INVESTOR'S BUSINESS DAILY)
Day One Biopharm Scores Relative Strength Rating Upgrade; Hits Key Threshold
Day One Biopharm Scores Relative Strength Rating Upgrade. Hits Key Threshold Investor's Business Daily ...
In Article Trend: Bullish
March 28, 2024 (11:08) / "Zacks Commentary" (by Zacks Equity Research)
Lyra Therapeutics ( LYRA ) Soars 6.5%: Is Further Upside Left in the Stock?
Lyra Therapeutics (LYRA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
In Article Trend: Somewhat-Bullish
March 28, 2024 (08:00) / "Investors Business Daily" (by Investor's Business Daily)
Stocks With Rising Relative Price Strength: Immunovant
When considering what names to put on your watch list, look for stocks with an 80 or higher RS Rating. Immunovant ( IMVT ) just met that criteria with a new score of 82. X IBD's unique RS Rating measures market leadership by showing how a stock's price action over the last 52 weeks compares to ...
In Article Trend: Somewhat-Bullish
March 27, 2024 (08:00) / "Investors Business Daily" (by INVESTOR'S BUSINESS DAILY)
Azenta Shows Rising Relative Price Performance; Still Shy Of Key Benchmark
Azenta Shows Rising Relative Price Performance. Still Shy Of Key Benchmark Investor's Business Daily ...
In Article Trend: Somewhat-Bullish
March 27, 2024 (08:00) / "Investors Business Daily" (by INVESTOR'S BUSINESS DAILY)
Madrigal Pharmaceuticals Shows Market Leadership With Jump To 81 RS Rating
Madrigal Pharmaceuticals ( MDGL ) saw a positive improvement to its Relative Strength ( RS ) Rating on Wednesday, rising from 76 to 81. X IBD's proprietary RS Rating identifies market leadership by showing how a stock's price action over the last 52 weeks measures up against that of other ...
In Article Trend: Somewhat-Bullish
March 25, 2024 (08:00) / "Investors Business Daily" (by Investor's Business Daily)
Celldex Therapeutics Reaches 80-Plus Relative Strength Rating Benchmark
The Relative Strength ( RS ) Rating for Celldex Therapeutics ( CLDX ) jumped into a new percentile Monday, with a rise from 79 to 82. X This unique rating identifies market leadership by using a 1 ( worst ) to 99 ( best ) score that indicates how a stock's price performance over the last 52 ...
In Article Trend: Neutral
March 22, 2024 (08:00) / "Investors Business Daily" (by INVESTOR'S BUSINESS DAILY)
Stocks With Rising Relative Price Strength: Structure Therap ADR
On Friday, Structure Therap ADR ( GPCR ) received an upgrade to its Relative Strength ( RS ) Rating, from 86 to 92. X IBD's unique rating identifies market leadership with a 1 ( worst ) to 99 ( best ) score.
In Article Trend: Somewhat-Bullish
March 21, 2024 (08:00) / "Investors Business Daily" (by Investor's Business Daily)
Stocks Showing Improving Market Leadership: Rocket Pharmaceuticals Earns 83 RS Rating
Rocket Pharmaceuticals ( RCKT ) had its Relative Strength ( RS ) Rating upgraded from 76 to 83 Thursday. X IBD's proprietary rating measures price movement with a 1 ( worst ) to 99 ( best ) score. The rating shows how a stock's price behavior over the trailing 52 weeks compares to all the ...
In Article Trend: Bullish
March 21, 2024 (08:00) / "Investors Business Daily" (by Investor's Business Daily)
Structure Therap ADR Shows Market Leadership With Jump To 86 RS Rating
On Thursday, Structure Therap ADR ( GPCR ) received a positive adjustment to its Relative Strength ( RS ) Rating, from 76 to 86. X IBD's unique rating identifies market leadership with a 1 ( worst ) to 99 ( best ) score.
In Article Trend: Somewhat-Bullish
March 21, 2024 (08:00) / "Investors Business Daily" (by INVESTOR'S BUSINESS DAILY)
Stocks With Rising Relative Strength: Syndax Pharmaceuticals
In a welcome move, Syndax Pharmaceuticals ( SNDX ) saw its Relative Strength Rating improve from 65 to 77 on Thursday. X IBD's unique RS Rating measures technical performance by showing how a stock's price action over the last 52 weeks compares to that of the other stocks in our database.
In Article Trend: Bullish
March 21, 2024 (08:00) / "Investors Business Daily" (by INVESTOR'S BUSINESS DAILY)
IBD Rating Upgrades: Sarepta Therapeutics Flashes Improved Price Strength
The Relative Strength ( RS ) Rating for Sarepta Therapeutics ( SRPT ) entered a higher percentile Thursday, as it got a lift from 69 to 76. X This exclusive rating from Investor's Business Daily identifies market leadership with a 1 ( worst ) to 99 ( best ) score.
In Article Trend: Bullish
March 21, 2024 (08:00) / "Investors Business Daily" (by INVESTOR'S BUSINESS DAILY)
IBD Rating Upgrades: Immunocore Holdings ADR Flashes Improved Relative Price Strength
Immunocore Holdings ADR ( IMCR ) had its Relative Strength ( RS ) Rating upgraded from 65 to 73 Thursday - a welcome improvement, but still shy of the 80 or better score you look for. X IBD's unique rating measures share price movement with a 1 ( worst ) to 99 ( best ) score.
In Article Trend: Bullish
March 21, 2024 (08:00) / "Investors Business Daily" (by Investor's Business Daily)
Celldex Therapeutics Scores Relative Strength Rating Upgrade; Hits Key Benchmark
Celldex Therapeutics Scores Relative Strength Rating Upgrade. Hits Key Benchmark Investor's Business Daily ...
In Article Trend: Somewhat-Bullish
March 21, 2024 (08:00) / "Investors Business Daily" (by Investor's Business Daily)
REGENXBIO Shows Rising Price Performance With Jump To 81 RS Rating
REGENXBIO ( RGNX ) saw a positive improvement to its Relative Strength ( RS ) Rating on Thursday, rising from 75 to 81. X This exclusive rating from Investor's Business Daily measures share price performance with a 1 ( worst ) to 99 ( best ) score.
In Article Trend: Bullish
March 20, 2024 (08:00) / "Investors Business Daily" (by Investor's Business Daily)
IBD Rating Upgrades: Xenon Pharmaceuticals Shows Improved Technical Strength
The Relative Strength ( RS ) Rating for Xenon Pharmaceuticals ( XENE ) jumped into a higher percentile Wednesday, as it got a lift from 69 to 75. X IBD's proprietary rating tracks market leadership with a 1 ( worst ) to 99 ( best ) score.
In Article Trend: Somewhat-Bullish
March 20, 2024 (08:00) / "Investors Business Daily" (by Investor's Business Daily)
Scholar Rock Holding Clears Technical Benchmark, Hitting 90-Plus RS Rating
Scholar Rock Holding ( SRRK ) had its Relative Strength ( RS ) Rating upgraded from 90 to 93 Wednesday. X This proprietary rating tracks technical performance by using a 1 ( worst ) to 99 ( best ) score that indicates how a stock's price performance over the trailing 52 weeks matches up ...
In Article Trend: Bullish
March 19, 2024 (14:35) / "Benzinga" (by Avi Kapoor)
Alpine Immune Sciences Analysts Boost Their Forecasts After Q4 Earnings - Alpine Immune Sciences ( NASDAQ:ALPN )
Alpine Immune Sciences, Inc. ALPN reported better-than-expected fourth-quarter financial results. Alpine Immune Sciences posted GAAP earnings of 15 cents per share, versus market estimates for a loss of 29 cents per share.
In Article Trend: Somewhat-Bullish
March 19, 2024 (14:03) / "Benzinga" (by Avi Kapoor)
National CineMedia Reports Upbeat Results, Joins Nordstrom, Core & Main And Other Big Stocks Moving Higher On Tuesday - Nordstrom ( NYSE:JWN ) , Core & Main ( NYSE:CNM ) , National CineMedia ( NASDAQ:NCMI )
U.S. stocks were mixed, with the Dow Jones index gaining around 75 points on Tuesday. Shares of National CineMedia, Inc. NCMI jumped 25.5% to $5.30 after the company posted upbeat results for its fourth quarter and disclosed a new $100 million share repurchase program.
In Article Trend: Somewhat-Bullish
March 19, 2024 (08:00) / "Investors Business Daily" (by INVESTOR'S BUSINESS DAILY)
Alpine Immune Sciences Gets A Composite Rating Upgrade
Alpine Immune Sciences ( ALPN ) saw an improvement in its IBD SmartSelect Composite Rating Tuesday, from 92 to 96. X The new rating is a sign the stock is outpacing 96% of all stocks when it comes to the most important stock-picking criteria.
In Article Trend: Somewhat-Bullish
March 19, 2024 (08:00) / "Investors Business Daily" (by Investor's Business Daily)
Stocks With Rising Relative Strength: Insmed
Insmed ( INSM ) saw a positive improvement to its Relative Strength ( RS ) Rating on Tuesday, rising from 69 to 73. X This unique rating measures market leadership by showing how a stock's price action over the last 52 weeks measures up against that of the other stocks in our database.
In Article Trend: Bullish
March 19, 2024 (08:00) / "Investors Business Daily" (by INVESTOR'S BUSINESS DAILY)
IBD Rating Upgrades: Supernus Pharmaceuticals Shows Improved Price Strength
The Relative Strength ( RS ) Rating for Supernus Pharmaceuticals ( SUPN ) jumped into a new percentile Tuesday, as it got a lift from 64 to 75. X IBD's unique RS Rating measures market leadership by showing how a stock's price movement over the last 52 weeks compares to that of the other ...
In Article Trend: Somewhat-Bullish
March 18, 2024 (23:25) / "Zacks Commentary" (by Zacks Equity Research)
Alpine Immune Sciences, Inc. ( ALPN ) Q4 Earnings and Revenues Beat Estimates
Alpine Immune Sciences, Inc. (ALPN) delivered earnings and revenue surprises of 146.88% and 346.89%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
In Article Trend: Neutral
March 15, 2024 (14:35) / "Zacks Commentary" (by Zacks Investment Research)
StoneCo ( STNE ) to Post Q4 Earnings: What's in the Offing?
StoneCo's (STNE) fourth-quarter 2023 performance will likely reflect strength in its financial services and software business.
In Article Trend: Somewhat-Bullish
March 14, 2024 (12:38) / "Zacks Commentary" (by Zacks Equity Research)
Is a Surprise Coming for Alpine Immune Sciences ( ALPN ) This Earnings Season?
Alpine Immune Sciences (ALPN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
In Article Trend: Bullish
March 13, 2024 (16:06) / "Zacks Commentary" (by Zacks Equity Research)
Will Revenue Decline Impact Jabil's ( JBL ) Q2 Earnings?
Jabil (JBL) is expected to report a top-line contraction year over year in the second quarter of fiscal 2024, owing to soft demand trends in several business segments.
In Article Trend: Somewhat-Bullish
March 11, 2024 (16:34) / "Zacks Commentary" (by Zacks Equity Research)
Adobe ( ADBE ) to Report Q1 Earnings: What's in the Offing?
Adobe's (ADBE) first-quarter fiscal 2024 results are expected to reflect gains from the solid momentum across the Digital Media and Digital Experience segments.
In Article Trend: Somewhat-Bullish
March 11, 2024 (14:00) / "Zacks Commentary" (by Zacks Equity Research)
Alpine Immune Sciences, Inc. ( ALPN ) Expected to Beat Earnings Estimates: Should You Buy?
Alpine Immune Sciences, Inc. (ALPN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
In Article Trend: Somewhat-Bullish
March 11, 2024 (13:18) / "Zacks Commentary" (by Zacks Investment Research)
SentinelOne ( S ) to Report Q4 Earnings: What's in the Cards?
SentinelOne's (S) fourth-quarter fiscal 2024 performance is expected to have benefited from its robust growth in the Singularity platform.
In Article Trend: Neutral
February 27, 2024 (23:35) / "Zacks Commentary" (by Zacks Equity Research)
Recursion Pharmaceuticals ( RXRX ) Reports Q4 Loss, Lags Revenue Estimates
Recursion Pharmaceuticals (RXRX) delivered earnings and revenue surprises of 13.04% and 11.92%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
In Article Trend: Neutral
Related stocks from Healthcare sector
Zynerba Pharmaceuticals, Inc. (ZYNE)
Qualigen Therapeutics, Inc. (QLGN)
Bausch + Lomb Corporation (BLCO)
Medtronic plc. (MDT)
Progenity, Inc. (PROG)
Spruce Biosciences, Inc. (SPRB)
Palatin Technologies, Inc. (PTN)
OrganiGram Holdings Inc. (OGI)
Zoetis Inc. (ZTS)
Tactile Systems Technology, Inc. (TCMD)
This website uses cookies to ensure you get the best experience on our website